bioAffinity Technologies, Inc.(BIAF)Earnings, Financials & Key Ratios
BIAF•NASDAQ
$2.12
$857186 mkt cap·Price updated May 7, 2026
AboutbioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.Show more
- Revenue$9M+269.7%
- EBITDA-$8M-8.1%
- Net Income-$9M-13.9%
- EPS (Diluted)-22.50+17.6%
- Gross Margin36.09%+15.4%
- EBITDA Margin-89.16%+70.8%
- Operating Margin-95.63%+69.6%
- Net Margin-96.56%+69.2%
- ROE-242.45%-142.8%
- ROIC-203.16%+40.7%
- Debt/Equity0.58+77.4%
- Interest Coverage-96.82+54.9%
BIAF Key Insights
bioAffinity Technologies, Inc. (BIAF) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 88 (top 12%)
- ✓Trading at only 0.3x book value
- ✓Efficient asset utilization: 1.4x turnover
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 38.7% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BIAF Price & Volume
bioAffinity Technologies, Inc. (BIAF) stock price & volume — 10-year historical chart
Loading chart...
BIAF Growth Metrics
bioAffinity Technologies, Inc. (BIAF) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-27.66%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-74.51%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.19%
Return on Capital
10 Years-106.96%
5 Years-106.96%
3 Years-106.96%
Last Year-190.84%
BIAF Peer Comparison
bioAffinity Technologies, Inc. (BIAF) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LUNG | 53.64M | 1.27 | -0.95 | 8.01% | -59.67% | -82.79% | 1.04 | |
 NVCR | 1.92B | 16.83 | -13.80 | 8.28% | -25.66% | -50.82% | 0.85 | |
 CDNA | 1.11B | 21.44 | -53.60 | 13.79% | -1.98% | -2.61% | 0.06 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 GKOS | 7.85B | 134.15 | -40.90 | 32.33% | -34.34% | -26.46% | 0.21 | |
 ILMN | 21.07B | 138.71 | 25.45 | -0.78% | 19.43% | 32.84% | 0.94 | |
 TMO | 176.36B | 474.56 | 26.75 | 3.91% | 15.18% | 13.23% | 0.76 | |
 DHR | 124.33B | 175.66 | 34.85 | 2.9% | 14.89% | 7.06% | 0.35 |
Compare BIAF vs Peers
bioAffinity Technologies, Inc. (BIAF) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BIAF Income Statement
bioAffinity Technologies, Inc. (BIAF) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 4.8K | 2.53M | 9.36M | 6.78M |
| Revenue Growth % | - | - | - | - | 52617.05% | 269.75% | -27.66% |
| Cost of Goods Sold | 40.28K | 22.24K | 4.82K | 467 | 1.74M | 5.98M | 5.16M |
| COGS % of Revenue | - | - | - | 9.72% | 68.76% | 63.91% | - |
| Gross Profit | -40.28K▲ 0% | -22.24K▲ 44.8% | -4.82K▲ 78.3% | 4.34K▲ 190.0% | 791.62K▲ 18156.8% | 3.38M▲ 326.8% | 1.62M▲ 0% |
| Gross Margin % | - | - | - | 90.28% | 31.26% | 36.09% | 23.92% |
| Gross Profit Growth % | - | 44.78% | 78.34% | 190.01% | 18156.8% | 326.85% | - |
| Operating Expenses | 3.05M | 2.58M | 2.2M | 4.02M | 8.77M | 12.33M | 12M |
| OpEx % of Revenue | - | - | - | 83601.79% | 346.17% | 131.72% | - |
| Selling, General & Admin | 1.2M | 972.1K | 875.96K | 2.48M | 6.79M | 9.94M | 9.8M |
| SG&A % of Revenue | - | - | - | 51656.09% | 268.21% | 106.21% | - |
| Research & Development | 1.85M | 1.61M | 1.33M | 1.52M | 1.73M | 1.78M | 1.94M |
| R&D % of Revenue | - | - | - | 31733.71% | 68.13% | 19.05% | - |
| Other Operating Expenses | 0 | 0 | 0 | 10.18K | 249.59K | 606K | 267.82K |
| Operating Income | -3.09M▲ 0% | -2.6M▲ 15.8% | -2.21M▲ 15.3% | -4.01M▼ 81.8% | -7.97M▼ 98.8% | -8.95M▼ 12.3% | -10.38M▲ 0% |
| Operating Margin % | - | - | - | -83511.51% | -314.89% | -95.63% | -153.2% |
| Operating Income Growth % | - | 15.78% | 15.27% | -81.76% | -98.78% | -12.29% | - |
| EBITDA | -3.05M | -2.58M | -2.2M | -4M | -7.72M | -8.35M | -9.85M |
| EBITDA Margin % | - | - | - | -83299.52% | -305.03% | -89.16% | -145.31% |
| EBITDA Growth % | - | 15.39% | 14.72% | -81.69% | -93.04% | -8.08% | -27.09% |
| D&A (Non-Cash Add-back) | 40.28K | 22.24K | 4.82K | 10.18K | 249.59K | 605.64K | 534.81K |
| EBIT | -3.09M | -6.88M | -5.32M | -5.62M | -7.88M | -8.94M | -14.64M |
| Net Interest Income | -212K | -381K | -1M | -2.49M | 85.01K | -74.86K | -48.62K |
| Interest Income | 2.78K | 0 | 424 | 46.71K | 122.13K | 17.61K | 7.72K |
| Interest Expense | 214.83K | 382.17K | 1M | 2.53M | 37.13K | 92.47K | 56.35K |
| Other Income/Expense | -212.06K | -4.66M | -4.12M | -4.14M | 57.21K | -75.35K | -4.32M |
| Pretax Income | -3.3M▲ 0% | -7.27M▼ 119.9% | -6.32M▲ 13.0% | -8.15M▼ 28.9% | -7.92M▲ 2.9% | -9.03M▼ 14.1% | -14.7M▲ 0% |
| Pretax Margin % | - | - | - | -169720.05% | -312.64% | -96.44% | -216.89% |
| Income Tax | 3.2K | 2.75K | 1.95K | 2.46K | 20.99K | 11.65K | 40.86K |
| Effective Tax Rate % | -0.1% | -0.04% | -0.03% | -0.03% | -0.27% | -0.13% | -0.28% |
| Net Income | -3.31M▲ 0% | -7.27M▼ 119.8% | -6.33M▲ 13.0% | -8.15M▼ 28.9% | -7.94M▲ 2.7% | -9.04M▼ 13.9% | -14.74M▲ 0% |
| Net Margin % | - | - | - | -169771.25% | -313.47% | -96.56% | -217.5% |
| Net Income Growth % | - | -119.77% | 12.96% | -28.89% | 2.66% | -13.9% | -74.51% |
| Net Income (Continuing) | -3.31M | -7.27M | -6.33M | -8.15M | -7.94M | -9.04M | -14.74M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -13.50▲ 0% | -29.70▼ 120.0% | -25.80▲ 13.1% | -54.30▼ 110.5% | -27.30▲ 49.7% | -22.50▲ 17.6% | -13.82▲ 0% |
| EPS Growth % | - | -120% | 13.13% | -110.47% | 49.72% | 17.58% | 15.19% |
| EPS (Basic) | -13.50 | -29.70 | -25.80 | -54.30 | -27.30 | -22.50 | - |
| Diluted Shares Outstanding | 245.93K | 245.93K | 245.93K | 149.97K | 291.6K | 404.33K | 1.07M |
| Basic Shares Outstanding | 245.93K | 245.93K | 245.93K | 149.97K | 291.6K | 404.33K | 1.07M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
BIAF Balance Sheet
bioAffinity Technologies, Inc. (BIAF) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 617.51K | 118.66K | 1.44M | 11.96M | 3.97M | 2.7M | 8.61M |
| Cash & Short-Term Investments | 578.48K | 83.11K | 1.36M | 11.41M | 2.82M | 1.11M | 7.67M |
| Cash Only | 578.48K | 83.11K | 1.36M | 11.41M | 2.82M | 1.11M | 7.67M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.53K | 1.53K | 1.53K | 10.49K | 811.67K | 1.14M | 448.99K |
| Days Sales Outstanding | - | - | - | 797.1 | 117.01 | 44.41 | 40.04 |
| Inventory | 0 | 28.35K | 0 | 5.54K | 18.48K | 27.61K | 35.23K |
| Days Inventory Outstanding | - | 465.27 | - | 4.33K | 3.88 | 1.68 | 2.58 |
| Other Current Assets | 37.49K | 5.67K | 59.3K | 191.82K | 124.69K | 147.18K | 460.19K |
| Total Non-Current Assets | 41.3K | 26.95K | 15.07K | 220.44K | 4.25M | 3.82M | 2.93M |
| Property, Plant & Equipment | 28.8K | 9.45K | 4.63K | 214.44K | 1.99M | 1.62M | 784.07K |
| Fixed Asset Turnover | - | - | - | 0.02x | 1.27x | 5.78x | 5.62x |
| Goodwill | 0 | 0 | 0 | 0 | 1.4M | 1.4M | 1.4M |
| Intangible Assets | 0 | 0 | 0 | 0 | 833.47K | 775.14K | 731.39K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 12.5K | 17.5K | 10.44K | 6K | 16.06K | 19.68K | 64.98K |
| Total Assets | 658.81K▲ 0% | 145.6K▼ 77.9% | 1.45M▲ 898.1% | 12.18M▲ 738.2% | 8.22M▼ 32.5% | 6.51M▼ 20.8% | 11.55M▲ 0% |
| Asset Turnover | - | - | - | 0.00x | 0.31x | 1.44x | 0.96x |
| Asset Growth % | - | -77.9% | 898.12% | 738.23% | -32.51% | -20.77% | -4.25% |
| Total Current Liabilities | 4.69M | 11.12M | 13.04M | 1.14M | 2.25M | 3.1M | 2.36M |
| Accounts Payable | 103.42K | 191.39K | 230.41K | 345.04K | 604.79K | 987.31K | 940.76K |
| Days Payables Outstanding | 937.18 | 3.14K | 17.46K | 269.68K | 126.79 | 60.23 | 79.28 |
| Short-Term Debt | 4.01M | 9.95M | 11.2M | 251.75K | 0 | 171.67K | 396.35K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 33.06K | 24.4K | 111.13K |
| Other Current Liabilities | 579.93K | 0 | 0 | 340.68K | 857.04K | 0 | 984.55K |
| Current Ratio | 0.13x | 0.01x | 0.11x | 10.50x | 1.77x | 0.87x | 0.87x |
| Quick Ratio | 0.13x | 0.01x | 0.11x | 10.50x | 1.76x | 0.86x | 0.86x |
| Cash Conversion Cycle | - | - | - | -264.55K | -5.91 | -14.13 | -36.66 |
| Total Non-Current Liabilities | 0 | 4.1M | 4.2M | 0 | 1.12M | 806.73K | 284.6K |
| Long-Term Debt | 0 | 53.47K | 160.18K | 0 | 0 | 20.18K | 284.6K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 1.12M | 786.55K | 1.71M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 4.04M | 4.04M | 0 | 0 | 0 | 3.97M |
| Total Liabilities | 4.69M | 15.22M | 17.24M | 1.14M | 3.37M | 3.91M | 2.64M |
| Total Debt | 4.01M | 10.01M | 11.36M | 251.75K | 1.58M | 1.5M | 680.95K |
| Net Debt | 3.43M | 9.92M | 10M | -11.16M | -1.24M | 395.9K | -6.99M |
| Debt / Equity | - | - | - | 0.02x | 0.33x | 0.58x | 0.58x |
| Debt / EBITDA | - | - | - | - | - | - | -0.07x |
| Net Debt / EBITDA | - | - | - | - | - | - | 0.71x |
| Interest Coverage | -14.39x | -6.81x | -2.20x | -1.58x | -214.76x | -96.82x | -259.85x |
| Total Equity | -4.04M▲ 0% | -15.07M▼ 273.5% | -15.79M▼ 4.8% | 11.04M▲ 169.9% | 4.86M▼ 56.0% | 2.6M▼ 46.4% | 8.9M▲ 0% |
| Equity Growth % | - | -273.5% | -4.76% | 169.94% | -56.04% | -46.41% | -96.01% |
| Book Value per Share | -16.41 | -61.29 | -64.21 | 73.64 | 16.65 | 6.44 | 8.35 |
| Total Shareholders' Equity | -4.04M | -15.07M | -15.79M | 11.04M | 4.86M | 2.6M | 8.9M |
| Common Stock | 18.72K | 18.72K | 18.74K | 58.67K | 65.76K | 106.59K | 24.26K |
| Retained Earnings | -14.92M | -22.19M | -28.51M | -36.67M | -44.6M | -53.64M | -65.42M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -18.72K | -4.04M | -4.04M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BIAF Cash Flow Statement
bioAffinity Technologies, Inc. (BIAF) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.49M | -2.21M | -2.05M | -4.07M | -6.04M | -7.26M | -7.26M |
| Operating CF Margin % | - | - | - | -84756.3% | -238.46% | -77.6% | - |
| Operating CF Growth % | - | 11.35% | 7.19% | -98.68% | -48.32% | -20.32% | -91.61% |
| Net Income | -3.31M | -7.27M | -6.33M | -8.15M | -7.94M | -9.04M | -14.74M |
| Depreciation & Amortization | 40.28K | 22.24K | 4.82K | 10.18K | 249.59K | 605.64K | 534.81K |
| Stock-Based Compensation | 0 | 275.73K | 43.01K | 248.59K | 748.82K | 989.68K | 772.31K |
| Deferred Taxes | 0 | 0 | 3.84M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 455.01K | 4.28M | -244.35K | 3.71M | 0 | 0 | 3.88M |
| Working Capital Changes | 322.01K | 482.62K | 632.82K | 114.2K | 900.79K | 179.72K | 1.11M |
| Change in Receivables | 290 | 0 | 0 | -8.96K | 311.37K | -327.53K | 878.18K |
| Change in Inventory | 0 | 0 | 0 | -5.54K | -12.94K | -9.12K | -9.87K |
| Change in Payables | -39.82K | 87.97K | 39.02K | 114.64K | -14.5K | 382.52K | 157.82K |
| Cash from Investing | -11.4K | -2.89K | 0 | -219.99K | -2.21M | -79.08K | -60.57K |
| Capital Expenditures | -11.4K | -2.89K | 0 | -219.99K | -22.9K | -79.08K | -60.57K |
| CapEx % of Revenue | - | - | - | 4580.2% | 0.9% | 0.84% | - |
| Acquisitions | 0 | 0 | 0 | 0 | -2.19M | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 2.33M | 1.72M | 3.33M | 14.34M | -344.98K | 5.63M | 15.42M |
| Debt Issued (Net) | 2.33M | 1.72M | 212.26K | 584.16K | -344.98K | -169.33K | -451.02K |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 0 | 1000K | 4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 3.11M | 7.73M | 0 | 1.45M | -1M |
| Net Change in Cash | 578.48K▲ 0% | -495.38K▼ 185.6% | 1.28M▲ 357.9% | 10.05M▲ 686.9% | -8.59M▼ 185.5% | -1.72M▲ 80.0% | 6.91M▲ 0% |
| Free Cash Flow | -2.5M▲ 0% | -2.21M▲ 11.6% | -2.05M▲ 7.3% | -4.29M▼ 109.4% | -6.06M▼ 41.2% | -7.34M▼ 21.2% | -8.51M▲ 0% |
| FCF Margin % | - | - | - | -89336.5% | -239.36% | -78.44% | -125.53% |
| FCF Growth % | - | 11.64% | 7.31% | -109.41% | -41.25% | -21.17% | -17.02% |
| FCF per Share | -10.17 | -8.99 | -8.33 | -28.61 | -20.78 | -18.16 | -18.16 |
| FCF Conversion (FCF/Net Income) | 0.75x | 0.30x | 0.32x | 0.50x | 0.76x | 0.80x | 0.58x |
| Interest Paid | 0 | 0 | 0 | 2.46K | 37.13K | 17.61K | 6.64K |
| Taxes Paid | 0 | 2.75K | 1.95K | 30.64K | 20.99K | 11.65K | 37.68K |
BIAF Key Ratios
bioAffinity Technologies, Inc. (BIAF) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -73.84% | -99.84% | -242.45% | -165.57% |
| Return on Invested Capital (ROIC) | - | - | - | -342.31% | -203.16% | -203.16% |
| Gross Margin | - | - | 90.28% | 31.26% | 36.09% | 23.92% |
| Net Margin | - | - | -169771.25% | -313.47% | -96.56% | -217.5% |
| Debt / Equity | - | - | 0.02x | 0.33x | 0.58x | 0.58x |
| Interest Coverage | -6.81x | -2.20x | -1.58x | -214.76x | -96.82x | -259.85x |
| FCF Conversion | 0.30x | 0.32x | 0.50x | 0.76x | 0.80x | 0.58x |
| Revenue Growth | - | - | - | 52617.05% | 269.75% | -27.66% |
BIAF Frequently Asked Questions
bioAffinity Technologies, Inc. (BIAF) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
bioAffinity Technologies, Inc. (BIAF) reported $6.8M in revenue for fiscal year 2024.
bioAffinity Technologies, Inc. (BIAF) grew revenue by 269.7% over the past year. This is strong growth.
bioAffinity Technologies, Inc. (BIAF) reported a net loss of $14.7M for fiscal year 2024.
Dividend & Returns
bioAffinity Technologies, Inc. (BIAF) has a return on equity (ROE) of -242.4%. Negative ROE indicates the company is unprofitable.
bioAffinity Technologies, Inc. (BIAF) had negative free cash flow of $8.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More BIAF
bioAffinity Technologies, Inc. (BIAF) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates